In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups

A recent article by The American Journal of Managed Care (AJMC), summarizes an analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition and co-authored by Ruemu E. Birhiray, MD of Hematology Oncology of Indiana showing that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib. Read the article.